Product Information
ORQUIDEA 0.35 MG TABLET is a generic product labeled by Xiromed LLC, priced at $0.0924 per EA under NDC 70700031685. Its NADAC has been published 60 times since Aug 13, 2025.
FDA first approved this application on Jun 24, 2013. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.35 mg/1
Manufacturer
Xiromed LLCNDC
70700031685
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
NORETHINDRONEApproval Type
Generic (ANDA)
FDA Application
ANDA201483FDA Approved
6/24/2013
TE Code
AB1
On Market Since
1/29/2025
Pharmacological Classes
Price Statistics
The NADAC for ORQUIDEA 0.35 MG TABLET has been published 60 times since Aug 13, 2025, and over the history we have for it it has risen 4.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0924 per EA |
|---|---|
| All-time high | $0.0945 (Apr 15, 2026) |
| All-time low | $0.0849 (Dec 17, 2025) |
| 52-week high | $0.0945 |
| 52-week low | $0.0849 |
| Median price | $0.0913 |
| Average price | $0.0911 |
| Largest weekly change | +5.3% (Jan 21, 2026) |
| Weeks tracked | 60 |
| Tracking since | Aug 13, 2025 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Xiromed LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
norethindrone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Progestin class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ORQUIDEA 0.35 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ORQUIDEA 0.35 MG TABLET, manufactured by Xiromed LLC, is $0.0924 per EA (NDC 70700031685), effective Sep 30, 2026.
How has the price of ORQUIDEA 0.35 MG TABLET changed over time?
Over the history we have for it, the NADAC for ORQUIDEA 0.35 MG TABLET has risen 4.7%. It has been tracked across 60 weekly CMS publications since Aug 13, 2025.
What are the highest and lowest recorded NADAC prices for ORQUIDEA 0.35 MG TABLET?
Since Aug 13, 2025, the NADAC for ORQUIDEA 0.35 MG TABLET has ranged from a low of $0.0849 (Dec 17, 2025) to a high of $0.0945 (Apr 15, 2026), with a median of $0.0913 per EA.
Are there cheaper alternatives to ORQUIDEA 0.35 MG TABLET?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, NORETHINDRONE 0.35 MG TABLET, is $0.0906 per EA — about 2% below ORQUIDEA 0.35 MG TABLET.
Who manufactures ORQUIDEA 0.35 MG TABLET?
ORQUIDEA 0.35 MG TABLET (NDC 70700031685) is labeled by Xiromed LLC, and CMS classifies it as a generic product.